Federal Register Notice: FDA has determined the regulatory review period for Genzyme Corp.’s Myozyme is 1,225 days for extending a patent which claims the human biological product. Myozome is indicated for use in patients with Pompe disease (GAA deficiency). To view this notice, click here.
